$262M+ Auxilium-Asahi Kasei Deal Expands Xiaflex Market
By Tom Wall
Wednesday, March 23, 2011
Auxilium Pharmaceuticals Inc. has added another piece to the expanding global market for Xiaflex (collagenase Clostridium histolyticum) with an agreement that gives Asahi Kasei Pharma Corp., of Tokyo, exclusive rights to commercialize Xiaflex for the treatment of Dupuytren's contracture and Peyronie's disease in Japan.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.